{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:22:55Z","timestamp":1782602575848,"version":"3.54.5"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Some sources urge caution when prescribing hydroxychloroquine (<jats:styled-content style=\"fixed-case\">HCQ<\/jats:styled-content>) to patients with G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content> deficiency, presumably due to a risk of hemolytic anemia. There are limited published data, however, to support this risk. Additionally, not all patients with G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content> deficiency are at similar risk for hemolysis, and people with the African variant are at particularly low risk. Through a retrospective chart review, we aimed to quantify the frequency of G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content>\u2010deficient patients with hemolysis attributed to <jats:styled-content style=\"fixed-case\">HCQ<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified Duke University Medical Center rheumatology patients with <jats:styled-content style=\"fixed-case\">HCQ<\/jats:styled-content> use and a measured G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content> level. A retrospective chart review was performed, recording demographics, G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content> levels, episodes of anemia, laboratory values consistent with hemolysis, and <jats:styled-content style=\"fixed-case\">HCQ<\/jats:styled-content> use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 275 patients reviewed, 84% were female; 46% were African American and 48% were white. The leading diagnoses were systemic lupus erythematosus (32%), rheumatoid arthritis (29%), and inflammatory arthritis (14%). Only 4% of patients were G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content> deficient (all African American). Two G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content>\u2010deficient patients had hemolysis during severe lupus flares that occurred while not taking <jats:styled-content style=\"fixed-case\">HCQ<\/jats:styled-content>. There were no reported episodes of hemolysis in more than 700 months of <jats:styled-content style=\"fixed-case\">HCQ<\/jats:styled-content> exposure among the 11 G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content>\u2010deficient patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This is the largest study to date evaluating G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content> deficiency with concurrent use of <jats:styled-content style=\"fixed-case\">HCQ<\/jats:styled-content>. Of 11 patients with G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content> deficiency, 2 had episodes of hemolysis, but these did not occur during <jats:styled-content style=\"fixed-case\">HCQ<\/jats:styled-content> therapy. These data do not support routine measurement of G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content> levels or withholding <jats:styled-content style=\"fixed-case\">HCQ<\/jats:styled-content> therapy among African American patients with G6<jats:styled-content style=\"fixed-case\">PDH<\/jats:styled-content> deficiency.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.23296","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T11:06:39Z","timestamp":1495796799000},"page":"481-485","source":"Crossref","is-referenced-by-count":65,"title":["Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6<scp>PDH<\/scp>\u2010Deficient Patients"],"prefix":"10.1002","volume":"70","author":[{"given":"Samya","family":"Mohammad","sequence":"first","affiliation":[{"name":"Duke University Medical Center Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E. B.","family":"Clowse","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Eudy","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Criscione\u2010Schreiber","sequence":"additional","affiliation":[{"name":"Duke University Medical Center Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39480"},{"key":"e_1_2_6_3_1","volume-title":"Drugs and supplements: hydroxychloroquine (oral route)","author":"Mayo Foundation for Medical Education and Research"},{"key":"e_1_2_6_4_1","volume-title":"Plaquenil (package insert)","year":"2015"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-077412"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.124.3220.484.b"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2008.12.005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.77.779"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0268-960X(96)90019-3","article-title":"G6PDH: population genetics and clinical manifestations","volume":"10","author":"Beutler E","year":"1996","journal-title":"Blood Rev"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-418"},{"issue":"63","key":"e_1_2_6_11_1","first-page":"2077","article-title":"The use of hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematosus: to check or not to check glucose\u20106\u2010phosphate dehydrogenase levels prior to its initiation in everyday rheumatology practice [abstract]","author":"Quinones M","year":"2011","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.7205\/MILMED.171.9.905"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536520-000000000-00000"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23296","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.23296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:32:38Z","timestamp":1759415558000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.23296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/acr.23296"],"URL":"https:\/\/doi.org\/10.1002\/acr.23296","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]}}}